1050477-31-0
1050477-31-0 structure
- Name: Finerenone
- Chemical Name: (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
- CAS Number: 1050477-31-0
- Molecular Formula: C21H22N4O3
- Molecular Weight: 378.42400
- Catalog: Signaling Pathways Metabolic Enzyme/Protease Mineralocorticoid Receptor
- Create Date: 2016-04-08 11:30:29
- Modify Date: 2026-07-03 19:54:05
-
Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease[1][2].
| Name | (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide |
|---|---|
| Synonyms |
Mr Neri ketone
Finerenone Inn (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-cboxamide Fenalidone Finerenone (BAY 2) BAY 2 Finerenone BAY948862 (DL)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl (S)-4-(4-Cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-cboxamide (4S)-4-(4-Cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-1,6-naphthyridine-3-cboxamide (Finerenone Impurity) BAY 2 Fenidone Finerenone API D5-Finerenone 1,6-Naphthyridine-3-cboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S) Finerone (4S)-4(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-1,6- naphthyridine-3-coxamide inhibit,cdiorenal,systolic,disease,pressure,Finerenone,diabetes,chronic,type,Inhibitor,kidney,Mineralocorticoid Rector,oral,nonsteroidal,blood Finerenone In-House UNII-DE2O63YV8R Finerenone, 10 mM in DMSO Non Nilidone |
| Description | Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease[1][2]. |
|---|---|
| Related Catalog | |
| In Vivo | Finerenone (BAY 94-8862) lowers albuminuria by >40% and significantly reduces systolic blood pressure (SBP) in Munich Wistar Frömter (MWF) rat[1]. Animal Model: Twelve-week-old MWF rat[1] Dosage: 10 mg/kg Administration: P.o.; daily for 4 weeks Result: Significantly reduced SBP in MWF rats; led to a significant reduction (>40%) in albuminuria in the MWF model. Animal Model: Twelve-week-old MWF rat[1] Dosage: 10 mg/kg Administration: P.o.; daily for 4 weeks Result: Significantly reduced SBP in MWF rats; led to a significant reduction (>40%) in albuminuria in the MWF model. |
| References |
| Molecular Formula | C21H22N4O3 |
|---|---|
| Molecular Weight | 378.42400 |
| Exact Mass | 378.16900 |
| PSA | 111.25000 |
| LogP | 4.27338 |
| Hazard Codes | T+ |
|---|